W. Jeffrey Allard, Ph.D.

  • Biochemist and immunologist with more than 25 years of experience
  • Sixteen successful commercial launches of new products
  • Six “New to the World” Products
  • Twelve patents for key diagnostic processes
  • Authored over 100 scientific papers and abstracts.
  • Eight scientific awards
  • Professional Achievement Award, Idaho State University
  • Three Bayer R&D achievement awards
  • Discovered, developed and commercialized a novel assay for Complexed PSA

Industry Employment:

  • Caris Life Science
  • Fujirebio Diagnostics
  • Immunicon
  • Bayer (Siemens Healthcare)
  • E. I. Dupont (Siemens Healthcare)
  • Merck Sharp and Dohme

Ph.D., Biochemistry, Dartmouth College
M.S., Immunology, Idaho State University
BS, Pre-Veterinary Medicine (cum laude), University of New Hampshire.

Dr. Allard served most recently as Director of Development for Caris Life Sciences where he designed and implemented a Product Development System, designed multiple clinical and regulatory strategies for novel multiplex oncology tests, wrote clinical protocols for prospective research and PMA-submission trials, and designed a Patient Registry. As Vice President and Chief Scientific Officer of Fujirebio Diagnostics, Inc. (FDI), Dr. Allard directed the Applied Research, Product Development, Clinical Affairs, Regulatory Affairs and Process Engineering Departments. He directed the US introduction of the Mesomark Assay as a Humanitarian Use Device for monitoring patients with mesothelioma. He also managed clinical trials leading to FDA clearance of HE4 for monitoring and for CA 125/HE4 and a logistic regression algorithm for differential diagnosis in women with pelvic mass. In addition, he managed FDI’s expanding global network of in-licensing institutions, and administered an international program in Clinical Research.! He also managed all intellectual property for FDI. Prior to joining FDI in 2004, Dr. Allard previously held positions as Vice President of Clinical Research and Development for Immunicon Corporation (Currently Veridex, LLC, a division of Johnson & Johnson) where he designed and managed clinical trials that led to worldwide introduction of the CellSearch Assay for measurement of circulating tumor cells (CTC). Dr. Allard designed three clinical trials that led to FDA clearance of CTC for prediction of overall survival and progression free survival in patients with breast, colorectal and prostate cancers. He was also Research Fellow and headed the effort in Clinical and Regulatory Oncology for Bayer Corporation (currently Siemens Medical Solutions Diagnostics) where he introduced novel immunoassays for complexed PSA and serum HER-2/neu along with a number of known cancer biomarkers.! Prior to joining Bayer, Dr. Allard was a Diagnostics Researcher for E.I. du Pont de Nemours (also currently a division of Siemens Medical Solutions Diagnostics).

Paul Allard
Director of Operations

Paul manages multiple key areas at Lakeside Life Science including Sales, Operations and IT.  He manages all product lines, coordinates with partners, and oversees shipping and receiving.

Paul has excelled as a student, athlete, and nurse. Paul is working toward his Bachelor of Science in Nursing and has worked as an LNA for the last five years.

Paul was inducted into PHI Theta Kappa international honor society in the spring of 2013, he received an award for excellence in the area of psychology in the same semester, while maintaining a 3.83 GPA overall.  As a student at the University of New Hampshire, Paul worked as a nationally certified peer educator on UNH’s main campus where he brought Drug and Alcohol awareness to his fellow students.